CJC-1295 w/o DAC: Research Overview

CJC-1295 without DAC (Drug Affinity Complex) is a synthetic analogue of growth hormone-releasing hormone (GHRH), representing a modified version of the first 29 amino acids of endogenous GHRH. Unlike CJC-1295 with DAC — which incorporates a maleimide group enabling albumin binding and extended half-life — the version without DAC has a shorter duration of action that more closely mimics the natural pulsatile pattern of GHRH secretion. This pharmacokinetic profile has made it particularly useful in research contexts where preserving the episodic nature of GH release is important for experimental design.

Mechanism of Action

CJC-1295 w/o DAC binds to GHRH receptors on pituitary somatotroph cells, triggering an intracellular signaling cascade involving adenylate cyclase and cyclic AMP (cAMP). This promotes the synthesis and pulsatile release of growth hormone into circulation. The GH released then acts on target tissues directly and stimulates IGF-1 production in the liver. Because CJC-1295 w/o DAC is cleared relatively quickly — with a half-life more similar to native GHRH — it produces GH pulses rather than sustained elevation, which researchers have found useful for studying physiologically appropriate GH dynamics.

Key Research Areas

• GH Pulsatility Research: The shorter half-life of CJC-1295 w/o DAC makes it valuable for studies examining the importance of GH pulse frequency and amplitude in downstream biological effects.
• IGF-1 Axis Studies: Animal models have used this compound to examine dose-response relationships between GHRH stimulation and circulating IGF-1 levels over time.
• Combination Protocols: Research has examined CJC-1295 w/o DAC in combination with Ipamorelin, where synergistic GH release occurs through dual receptor system activation.
• Metabolic and Body Composition Models: Preclinical studies have explored effects on lean body mass, fat mobilization, and nitrogen retention in various metabolic research frameworks.

Research Applications

CJC-1295 w/o DAC is commonly used in endocrinology and metabolic research, often in combination with growth hormone secretagogues like Ipamorelin to study synergistic GH stimulation. It is administered subcutaneously in rodent studies, with timing protocols designed to capture specific GH pulse dynamics. In vitro applications include pituitary cell culture systems where GHRH receptor signaling and GH secretion can be directly measured.

Storage and Handling

CJC-1295 w/o DAC is supplied as a lyophilized powder. Store at -20°C in a dry, light-protected environment. Reconstitute with sterile bacteriostatic water using aseptic technique. Once reconstituted, store at 2–8°C and use within 28 days. Avoid freeze-thaw cycles to preserve peptide integrity.

Available from Alpha Peptides US

Alpha Peptides US offers CJC-1295 w/o DAC 10mg for qualified laboratory research. Suitable for GH axis studies, endocrinology research, and combination peptide protocols.

This product is intended for laboratory research purposes only. It is not approved by the FDA and is not intended for human or veterinary use, diagnosis, treatment, or prevention of any condition.